Enoxaparin: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
'''''For patient information about Enoxaparin, click [[Enoxaparin (patient information)|here]]''''' | '''''For patient information about Enoxaparin, click [[Enoxaparin (patient information)|here]]''''' | ||
{{SB}} LOVENOX<sup>®</sup> | {{SB}} LOVENOX<sup>®</sup> | ||
{| | |||
|- | |||
|[[File:ENOXAPARINO1.jpg|thumb|800px]] | |||
|- | |||
|} | |||
==Overview== | ==Overview== | ||
Revision as of 02:28, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Enoxaparin, click here Synonyms / Brand Names: LOVENOX®
 |
Overview
Category
Cardiovascular Drugs:Antiplatelet drugs
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages